CTAD: Sigma-1 receptor agonist passes muster in small Alzheimer’s trial
November 17, 2015|Internal Medicine News
Author and Disclosure Information
AT CTAD
Patients who have completed 12 weeks of treatment in the 52-week extension trial experienced a mean improvement of 3.2 points on the ADCS-ADL measure. The difference, while not statistically significant, is encouraging at this point in treatment, Dr. Macfarlane said.
Dr. Macfarlane has no financial interest in Anavex 2-73, and has no financial disclosures.
